MONISTAT 1 COMBINATION PACK (miconazole nitrate) by Design Pharmaceuticals is clinical pharmacology miconazole nitrate exhibits fungicidal activity in vitro against species of the genus candida. First approved in 2001.
Drug data last refreshed 3h ago · AI intelligence enriched 1w ago
MONISTAT 1 is a vaginal antifungal combination pack containing miconazole nitrate for treatment of vulvovaginal candidiasis. The drug exhibits fungicidal activity against Candida species through an unknown pharmacologic mechanism. It is administered as a topical vaginal cream and suppository formulation.
Product is approaching loss of exclusivity with moderate competitive pressure (30), indicating transition from growth to defense and potential headcount reduction on brand team.
CLINICAL PHARMACOLOGY Miconazole nitrate exhibits fungicidal activity in vitro against species of the genus Candida. The pharmacologic mode of action is unknown. Following intravaginal administration of miconazole nitrate, small amounts are absorbed. Administration of a single dose of miconazole…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Prospective Two-Year Study to Assess Miconazole Nitrate Resistance in Neonates and Infants
Worked on MONISTAT 1 COMBINATION PACK at Design Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on MONISTAT 1 offers experience in mature product lifecycle management, competitive defense strategies, and OTC-to-Rx channel expertise in a crowded market. Career growth is limited; this role is best suited for professionals managing LOE transitions or building defensive marketing skills.